eligibility_summary
Eligible: Metastatic breast cancer patients with a liver, lung, pleural, or bone biopsy in the metastatic setting between Jan 1, 2005 and Jan 1, 2024. Exclude: no CT or PET-FDG imaging within 3 months before biopsy or prior treatment interruption, unknown HER2 status, or biopsy site is lymph node, soft tissue, or other visceral organ.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational, retrospective radiomics study in metastatic breast cancer assessing a CT/PET-based “radiobiopsy” to predict HER2 status (0/low/overexpressed) and efficacy of trastuzumab deruxtecan (T-DXd, DS-8201a). Drug/intervention: T-DXd—an anti-HER2 antibody-drug conjugate (trastuzumab IgG1 linked to the topoisomerase I inhibitor deruxtecan). Mechanism: binds HER2 on tumor cells, internalizes, releases DXd to inhibit topo I and induce DNA damage, membrane-permeable payload enables a bystander effect, Fc may support ADCC. Targets: HER2-expressing breast cancer cells and the HER2 pathway, payload targets DNA replication/repair via topo I. The study also maps intra- and inter-lesion HER2 heterogeneity via radiomics/pathomics and explores immune and metabolic transcriptomic signatures tied to radiomic features and T-DXd outcomes (e.g., PFS).